Join to access to all OVN content. Join for Free

Results for 'Think Again'

...
Partner Avatar Tom Caravela
MSL People Skills: Top 10 Tips for Better Engagement

Apr 20th • 8 mins read

...
Partner Avatar Tom Caravela
Promotability: How to Land Your Next Promotion

May 5th • 10 mins read

...
Partner Avatar Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022

Dec 21st • 10 mins read

...
Partner Avatar Tom Caravela
What to do When a Job Offer is Rescinded

Jul 20th • 5 mins read

...
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

May 6th • 18 mins read

...
OVN Avatar Xuanyi Li, Elizabeth A. Sigworth, Adrianne H. Wu, Jess Behrens, Shervin A. Etemad, Seema Nagpal, Ronald S. Go, Kristin Wuichet, Eddy J. Chen, Samuel M. Rubinstein, Neeta K. Venepalli, Benjamin F. Tillman, Andrew J. Cowan, Martin W. Schoen, Andrew Malty, J
Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis

Oct 16th • 12 mins read

...
OVN Avatar Siddharth Agrawal, Nidhi Bansal
Advances and Challenges in Pediatric and Childhood Cancers

Jun 27th • 2 mins read

...
OVN Avatar Christopher A. Busch, MSC; Johannes Krisam, PhD; Meinhard Kieser, PhD
A Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials—A Simulation Study

Jun 28th • 30 mins read

...
OVN Avatar K. Ribi, N. Kalbermatten, M. Eicher, F. Strasser
Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent

Jun 1st • 25 mins read

...
Partner Avatar Envision Pharma Group
Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

May 9th • 5 mins read

...
OVN Avatar Francesco Cerisoli, PhD, Farzad Ali, MSc, Tamás Bereczky, MA, PhD, Natacha Bolaños, BS, Lars Bullinger, MD, Sujith Dhanasiri, MPhil, MSc, James Gallagher, PhD, Sonia García Pérez, MSc, Jan Geissler, MiBA, Yann Guillevic, DEA, Kathryn Harrison, PhD, Anasta
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

May 17th • 12 mins read

...
OVN Avatar Jonathan H Seltzer MD, MBA, MA, Gary Gintant PhD, Laleh Amiri-Kordestani MD, Jack Singer MD, Luana Pesco Koplowitz MD, PhD, Javid J Moslehi MD, Ana Barac MD, PhD, Anthony F. Yu MD
Assessing cardiac safety in oncology drug development

Jun 12th • 12 mins read